Velbionanotech is designing drugs for various diseases such as Heart Disease, kidney stones, AIDS, Cancer, cosmetic generic products using a short fragment of DNA as a new type of drugs. These drugs are assembled in Nanochips and as nano particals for delivering in human body, which are affective in curing the sick/diseased and healing the injured. nVBN are working into New gene therapy procedures, DNA-based sensors, and other medical applications by using a new method developed to initiate and control chemical reactions on DNA strands. On the other hand silicon-based nanochips with itching and self-assembling techniques used to deliver drugs on the diseased molecules. The company are designing bionano products for the treatment of various diseases for Kidney stones,Gallbladder,Liver, Lungs,Heart etc mixing biology with traditional machinery. VBN Nanomedicine prepared for Heart disease, Galbladder, Liver, Kidney stones will have no side effect and it is safe to use since it is herbal. nn

Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.

CoImmune is involved in the development and manufacture of cell-based therapeutics within the healthcare sector. The company works on treatments for cancer, autoimmune, and inflammatory diseases. Its clientele includes sectors seeking medical therapies for complex conditions. CoImmune was formerly known as Argos Therapeutics. It was founded in 1997 and is based in Durham, North Carolina. CoImmune operates as a subsidiary of Genexine and SCM Lifescience.

Rockfish Bio focuses on the development of senolytic therapies within the biotechnology sector. The company's main offerings include compounds designed to treat age-related diseases by targeting and eliminating senescent cells to promote healthy aging. Rockfish Bio's therapies are applicable to a range of conditions such as chronic kidney disease, liver fibrosis, and neurodegenerative diseases. It was founded in 2021 and is based in Wien, Austria.

Profectus Biosciences is a technology based vaccine company devoted to the treatment and prevention of chronic viral diseases. The Company's name, Profectus, when translated from its Latin roots, means"to advance or improve". The Company's proof of concept target is human immunodeficiency virus (HIV) with an intermediate term focus on hepatitis C virus (HCV).

Amplimmune is a product driven company that is developing immune-based biologics to treat patients in the areas of cancer, autoimmunity, transplantation and infectious diseases. Amplimmune's scientific founders from Johns Hopkins University have identified several key immunological ligands and receptors. These immunological checkpoint and co-stimulatory molecules are the basis for developing a new class of biological treatments which modulate critical mechanisms in the body's immune system with the aim of bettering the lives of patients suffering from aberrant immunological conditions.